FDA Developing Brand/Generic Labeling “Carve Out” Notification Process
Executive Summary
FDA is developing a process to inform innovators and generic companies when part of a brand drug's labeling can be "carved out" of an ANDA, Associate Counsel for Drugs Elizabeth Dickinson said